Atherosclerosis
Volume 188, Issue 2 , Pages 231-244 , October 2006

Adiponectin and its gene variants as risk factors for insulin resistance, the metabolic syndrome and cardiovascular disease

  • D.R. Gable

      Affiliations

    • Centre for Cardiovascular Genetics, British Heart Foundation Laboratories, Royal Free & UCL Medical School, The Rayne Institute, 5 University Street, London WC1E 6JF, United Kingdom
    • Corresponding Author InformationCorresponding author. Tel.: +44 20 76796964; fax: +44 20 76796212.
    • ,
  • S.J. Hurel

      Affiliations

    • Department of Diabetes and Endocrinology, UCLH NHS Foundation Trust, 3rd Floor Central, 250 Euston Road, London NW1 2PQ, United Kingdom
    • ,
  • S.E. Humphries

      Affiliations

    • Centre for Cardiovascular Genetics, British Heart Foundation Laboratories, Royal Free & UCL Medical School, The Rayne Institute, 5 University Street, London WC1E 6JF, United Kingdom

Received 4 August 2005 ,Revised 16 November 2005 ,Accepted 1 February 2006.

References 

  1. Flegal KM, Carroll MD, Ogden CL, Johnson CL. Prevalence and trends in obesity among US adults, 1999–2000. JAMA. 2002;288:1723–1727
  2. Expert panel on detection, evaluation and treatment of high blood cholesterol in adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001;285:2486–2497
  3. Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 2001;24:683–689
  4. Alberti KGMM, Zimmet P, Shaw J. The metabolic syndrome—a new worldwide definition. The Lancet. 2005;366:1059–1062
  5. Kahn R, Buse J, Ferrannini E, Stern M. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2005;28:2289–2304
  6. Rajala MW, Scherer PE. Minireview: the adipocyte-at the crossroads of energy homeostasis, inflammation, and atherosclerosis. Endocrinology. 2003;144:3765–3773
  7. Hug C, Lodish HF. Visfatin: a new adipokine. Science. 2005;307:366–367
  8. Arita Y, Kihara S, Ouchi N, et al. Paradoxical decrease of an adipose-specific protein; adiponectin, in obesity. Biochem Biophys Res Commun. 1999;257:79–83
  9. Halleux CM, Takahashi M, Delporte ML, et al. Secretion of adiponectin and regulation of apM1 gene expression in human visceral adipose tissue. Biochem Biophys Res Commun. 2001;288:1102–1107
  10. Shapiro L, Scherer PE. The crystal structure of a compliment C1q family protein suggests an evolutionary link to tumour necrosis factor. Curr Biol. 1998;8:335–338
  11. Wong GW, Wang J, Hug C, Tsao TS, Lodish HF. A family of Arcp30/adiponectin structural and functional paralogs. Proc Natl Acad Sci. 2004;101:10302–10307
  12. Yokota T, Oritani K, Takahashi I, et al. Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood. 2000;96:1723–1732
  13. Pajvani UB, Du X, Combs TP, et al. Structure–function studies of the adipocyte-secreted hormone Acrp30/adiponectin. Implications for metabolic regulation and bioactivity. J Biol Chem. 2003;278:9073–9085
  14. Fruebis J, Tsao TS, Javorschi S, et al. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci. 2001;98:2005–2010
  15. Yamauchi T, Kamon J, Ito Y, et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature. 2003;423:762–769
  16. Hug C, Wang J, Ahmed NS, et al. T-cadherin is a receptor for hexameric and high molecular weight forms of Arcp 30/adiponectin. Proc Natl Acad Sci. 2004;101:10308–10313
  17. Kadowaki T, Yamauchi T. Adiponectin and adiponectin receptors. Endocr Rev. 2005;26:439–451
  18. Maeda N, Shimomura I, Kishida K, et al. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med. 2002;8:731–737
  19. Yamauchi T, Kamon J, Waki H, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med. 2001;7:941–946
  20. Xu A, Wang Y, Keshaw H, et al. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest. 2003;112:91–100
  21. Yamauchi T, Kamon J, Minokoshi Y, et al. Adiponectin stimulates glucose utilisation and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med. 2002;8:1288–1295
  22. Adamczak M, Rzepka E, Chudek J, Wiecek A. Ageing and plasma adiponectin concentrations in apparently healthy males and females. Clin Endocrinol. 2005;62:114–118
  23. Lanfranco F, Zitzman M, Simoni M, Nieschlag E. Serum adiponectin levels in hypogonadal males: influence of testosterone replacement therapy. Clin Endocrinol. 2004;500–507
  24. Hotta K, Funahashi T, Arita Y, et al. Plasma concentrations of a novel, adipose specific protein adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol. 2000;20:1595–1599
  25. Yang WS, Lee WJ, Funahashi T, et al. Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. J Clin Endocrinol Metab. 2001;86:3815–3819
  26. Maeda N, Takahashi M, Funahashi T, et al. PPARγ ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes. 2005;50:2094–2099
  27. Nilsson L, Binart N, Bohlooly Y, et al. Prolactin and growth hormone regulate adiponectin secretion and receptor expression in adipose tissue. Biochem Biophys Res Commun. 2005;331:1120–1126
  28. Zhang Y, Matheny M, Zolotukhin S, Tumer N, Scarpace PJ. Regulation of adiponectin and leptin gene expression in white and brown adipose tissues: influence of β3-adrenergic agonists, retinoic acid, leptin and fasting. Biochem Biophys Acta. 2002;1584:115–122
  29. Fasshauer M, Klein J, Neumann S, Eszlinger M, Paschke R. Hormonal regulation of adiponectin gene expression in 3T3-L1 adipocytes. Biochem Biophys Res Commun. 2002;290:1084–1089
  30. Choi KM, Lee KW, Seo JA, et al. The association between plasma adiponectin, gherlin levels and cardiovascular risk factors. Eur J Endocrinol. 2004;150:715–718
  31. Zietz B, Herfarth H, Paul G, et al. Adiponectin represents an independent cardiovascular risk factor predicting serum HDL-cholesterol levels in type 2 diabetes. FEBS Lett. 2003;545:103–104
  32. Nakamura Y, Shimada K, Fukada D, et al. Implications of plasma concentrations of adiponectin in patients with coronary artery disease. Heart. 2004;90:528–533
  33. Higashiura K, Ura N, Ohata J, et al. Correlations of adiponectin level with insulin resistance and atherosclerosis in Japanese male populations. Clin Endocrinol. 2004;61:753–759
  34. Chan KC, Chou HH, Wu DJ, Wu YL, Huang CN. Diabetes mellitus has an additional effect on coronary artery disease. To decrease adiponectin levels. Jpn Heart J. 2004;45:921–927
  35. Shetty GK, Economides PA, Horton ES, Mantzoros CS, Veves A. Circulating adiponectin and resistin levels in relation to metabolic factors, inflammatory markers and vascular reactivity in diabetic patients and subjects at risk for diabetes. Diabetes Care. 2004;27:2450–2457
  36. Singhal A, Jamieson N, Fewtrell M, et al. Adiponectin predicts insulin resistance but not endothelial function in young healthy adolescents. J Clin Endocrinol Metab. 2005;[Epub 10/05/05]
  37. Kojima S, Funahashi T, Maruyoshi H, et al. Levels of the adipocyte-derived plasma protein, adiponectin, have a close relationship with atheroma. Thromb Res. 2005;115:483–490
  38. Butte NF, Comuzzie AG, Cai G, et al. Genetic and environmental factors influencing fasting serum adiponectin in hispanic children. J Clin Endocrinol Metab. 2005;90:4170–4176
  39. Pellemé F, Smith U, Funahashi T, et al. Circulating adiponectin levels are reduced in nonobese but insulin-resistant first-degree relatives of type 2 diabetic patients. Diabetes. 2003;52:1182–1186
  40. Schulze MB, Rimm E, Shai I, Rifai N, Hu FB. Relationship between adiponectin and glycemic control, blood lipids, and inflammatory markers in men with type 2 diabetes. Diabetes Care. 2004;27:1680–1687
  41. Winzer C, Wagner O, Festa A, et al. Plasma adiponectin, insulin sensitivity, and subclinical inflammation in women with prior gestational diabetes mellitus. Diabetes Care. 2004;27:1721–1727
  42. Fernandez-Real JM, Lopez-Bermejo A, Casamitjana R, Ricart W. Novel interactions of adiponectin with the endocrine system and inflammatory parameters. J Clin Endocrinol Metab. 2003;88:2714–2718
  43. Mantzoros CS, Li T, Manson JE, Meigs J, Hu FB. Circulating adiponectin levels are associated with better glycemic control, more favorable lipid profile, and reduced inflammation in women with type 2 diabetes. J Clin Endocrinol Metab. 2005;90:4542–4548
  44. Martin LJ, Woo JG, Daniels SR, Goodman E, Dolan LM. The relationships of adiponectin with insulin and lipids are strengthened with increasing adiposity. J Clin Endocrinol Metab. 2005;90:4255–4259
  45. Valsamakis G, Chetty R, McTernan PG, et al. Fasting serum adiponectin concentration is reduced in Indo-Asian subjects and is related to HDL cholesterol. Diabet Obes Metabol. 2003;5:131–135
  46. Bugianesi E, Pagotto U, Manini R, et al. Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity. J Clin Endocrinol Metab. 2005;90:3498–3504
  47. Targher G, Bertolini L, Scala L, Poli F, Zenari L, Falezza G. Decreased plasma adiponectin concentrations are closely associated with nonalcoholic hepatic steatosis in obese individuals. Clin Endocrinol. 2004;61:700–703
  48. Tshritter O, Fritsche A, Thamer C, et al. Plasma adiponectin concentrations predict insulin sensitivity of both glucose and lipid metabolism. Diabetes. 2003;52:239–243
  49. Gonzalez-Sanchez JL, Zabena CA, Martinez-Larrad MT, et al. An SNP in the adiponectin gene is associated with decreased serum adiponectin levels and risk for impaired glucose tolerance. Obes Res. 2005;13:807–812
  50. Salmenniemi U, Zacharova J, Ruotsalainen E, et al. Association of adiponectin level and variants in the adiponectin gene with glucose metabolism, energy expenditure and cytokines in offspring of type 2 diabetic patients. J Clin Endocrinol Metab. 2005;90:4216–4223
  51. Weyer C, Funahashi T, Tanaka S, et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab. 2001;86:1930–1935
  52. Lihn AS, Østergärd T, Nyholm B, et al. Adiponectin expression in adipose tissue is reduced in first-degree relatives of type 2 diabetic patients. AJP: Endocrinol Metab. 2003;284:443–448
  53. Stefan N, Vozarova B, Funahashi T, et al. Plasma adiponectin concentration is associated with skeletal muscle insulin receptor tyrosine phosphorylation, and low plasma concentration precedes a decrease in whole-body insulin sensitivity in humans. Diabetes. 2002;50:1884–1888
  54. Thamer C, Machann J, Tschritter O, et al. Relationship between serum adiponectin concentration and intramyocellular lipid stores in humans. Horm Metab Res. 2003;34:646–649
  55. Tomas E, Tsao TS, Saha AK, et al. Enhanced muscle fat oxidation and glucose transport by ARCP30 globular domain: acetyl-coA carboxylase inhibition and AMP-activated protein kinase activation. Proc Natl Acad Sci. 2002;99:16309–16313
  56. Fu Y, Luo N, Klein RL, Garvey WT. Adiponectin promotes adipocyte differentiation, insulin sensitivity, and lipid accumulation: potential role in autoregulation of adipocyte metabolism and adipose mass. J Lipid Res. 2005;46:1369–1379
  57. Hotamisligil GS, Shargill NS, Spieglman BM. Adipocyte expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science. 1993;259:87–91
  58. Kahn BB, Alquier T, Carling D, Hardie DG. AMP-activated protein kinas: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab. 2005;1:15–25
  59. Ruderman NB, Saha AK, Kraegen EW. Minireview: malonylCoA, AMP-activated protein kinase, and adiposity. Endocrinology. 2003;144:5166–5171
  60. Zurlo F, Lillioja S, Esposito-Del PA, et al. Low ratio of fat to carbohydrate oxidation as predictor of weight gain: study of 24-h RQ. AJP: Endocrinol Metab. 1990;259:E650–E657
  61. Larson DE, Ferraro RT, Robertson DS, Ravussin E. Energy metabolism in weight-stable postobese individuals. Am J Clin Nutr. 1995;62:739
  62. Weiss R, Taksali SE, Dufour SD, et al. The “obese insulin-sensitive” adolescent: importance of adiponectin and lipid partitioning. J Clin Endocrinol Metab. 2005;90:3731–3737
  63. Nedvidkova J, Smitka K, Hainer V. Adiponectin, an adipocyte-derived protein. Physiol Res. 2005;54:133–140
  64. Tataranni PA, Ortega E. A burning question. Does an adipokine-induced activation of the immune system mediate the effect of overnutrition in type 2 diabetes. Diabetes. 2005;54:927
  65. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. NEJM. 2005;352:1685–1695
  66. Okomoto Y, Kihara S, Ouchi N, et al. Adiponectin reduces atherosclersosis in apolipoprotein E-deficient mice. Circulation. 2002;106:2767–2770
  67. Ouchi N, Ohishi M, Kihara S, et al. Association of hypoadiponectinemia with impaired vasoreactivity. Hypertension. 2003;42:231–234
  68. Shibata R, Ouchi N, Ito M, et al. Adiponectin-mediated modulation of hypertrophic signals in the HEART. Nat Med. 2004;12:1384–1389
  69. Shimbukuro M, Higa N, Asahi T, et al. Hypoadiponectinemia is closely linked to endothelial dysfunction in man. J Clin Endocrinol Metab. 2003;88:3236–3240
  70. Fernandez-Real JM, Castro M, Vazquez G, et al. Adiponectin is associated with vascular function independent of insulin sensitivity. Diabetes. 2004;27:739–745
  71. Tan KCB, Xu A, Chow WS, et al. Hypoadiponectinemia is associated with impaired endothelium-dependent vasodilation. J Clin Endocrinol Metab. 2004;89:765–769
  72. Diez JJ, Igelias P, Fernandez-Reyes MJ, et al. Serum concentrations of leptin, adiponectin and resistin, and their relationship with cardiovascular disease in patients with end stage renal disease. Clin Endocrinol. 2005;62:242–249
  73. Ignacy I, Chudek J, Adamczak M, et al. Reciprocal association of plasma adiponectin and serum C-reactive protein concentration in haemodialysis patients with end stage kidney disease: a follow up study. Nephron Clin Pract. 2005;101:18–24
  74. Bruun JM, Lihn AS, Verdich C, et al. Regulation of adiponectin by adipose tissue-derived cytokines: in vivo and in vitro investigations in humans. AJP: Endocrinol Metab. 2003;285:E527–E533
  75. Iwashima Y, Katsuya T, Ishikawa K, et al. Hypoadiponectinemia is an independent risk factor for hypertension. Hypertension. 2004;43:1318–1323
  76. Ouchi N, Kihara S, Funahashi T, et al. Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation. 2003;107:671–674
  77. Pilz S, Horejsi R, Möller R, et al. Early atherosclerosis in obese juveniles is associated with low serum levels of adiponectin. J Clin Endocrinol Metab. 2005;90:4792–4796
  78. Yilmaz MI, Sonmez A, Kilic S, et al. The association of plasma adiponectin levels with hypertensive retinopathy. Eur J Endocrinol. 2005;152:233–240
  79. Komatsu M, Ohfusa H, Sato Y, et al. Strong inverse correlation between serum adiponectin and heart rate-corrected QT interval in an apparently healthy population. Diabetes Care. 2004;27:1237–1238
  80. Iwashima Y, Katsuya T, Ishikawa K, et al. Association of hypoadiponectinemia with smoking habit in men. Hypertension. 2005;45:1094–1100
  81. Thamer C, Stefan N, Stumvoll M, Haring H, Fritsche A. Reduced adiponectin serum levels in smokers. Atherosclerosis. 2004;179:421–422
  82. Iacobellis G, Pistilli D, Gucciardo M, et al. Adiponectin expression in human epicardial adipose tissue in vivo is lower in patients with coronary artery disease. Cytokine. 2005;29:251–255
  83. Kojima S, Funahashi T, Sakamoto T, et al. The variation of plasma concentrations of a novel, adipocyte derived protein, adiponectin, in patients with acute myocardial infarction. Heart. 2003;89:667–668
  84. Nakanishi S, Yamane K, Kamei N, et al. A protective effect of adiponectin against oxidative stress in Japanese Americans: the association between adiponectin or leptin and urinary isoprostane. Metab Clin Exp. 2005;54:194–199
  85. Chen MP, Tsai JCR, Chung FM, et al. Hypoadiponectinemia is associated with ischemic cerebrovascular disease. Arterioscler Thromb Vasc Biol. 2005;25:821–826
  86. Kawano T, Saito T, Yasu T, et al. Close association of hypoadiponectinemia with arteriosclerosis obliterans and ischemic heart disease. Metab Clin Exp. 2005;54:653–656
  87. Kumada M, Kihara S, Sumitsuji S, et al. and for the Osaka CAD Study Group Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol. 2003;23:85–89
  88. Pischon T, Girman CJ, Hotamisligil GS, et al. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA. 2004;291:1730–1737
  89. Costacou T, Zgibor JC, Evans RW, et al. The prospective association between adiponectin and coronary artery disease among individuals with type 1 diabetes. The Pittsburgh Epidemiology of Diabetes Complications Study. Diabetologia. 2005;48:41–48
  90. Ajuwon KM, Spurlock ME. Adiponectin inhibits LPS-induced NF-κB activation and IL-6 production and increases PPARγ2 expression in adipocytes. Am J Physiol Regul Comp Physiol. 2005;288:R1220–R1225
  91. Okomoto Y, Arita Y, Nishida M, et al. An adipocyte-derived plasma protein, adiponectin, adheres to injured vascular walls. Horm Metab Res. 2000;32:47–50
  92. Chen H, Montagnani M, Funahashi T, Shimomura I, Quon M. Adiponectin stimulates production of nitric oxide in vascular endothelial cells. J Biol Chem. 2003;278:45021–45026
  93. Kobayashi H, Ouchi N, Kihara S, et al. Selective suppression of endothelial cell apoptosis by the high molecular weight form of adiponectin. Circ Res. 2004;94:e27–e31
  94. Brakenhielm E, Veitonmaki N, Cao R, et al. Adiponectin-induced antiangiogenesis and antitumor activity involve caspase-mediated endothelial cell apoptosis. Proc Natl Acad Sci. 2005;2476–2481
  95. Kawanami D, Maemura K, Takeda N, et al. Direct reciprocal effects of resistin and adiponectin on vascular endothelial cells: a new insight into adipocytokine-endothelial cell interactions. Biochem Biophys Res Commun. 2004;314:415–419
  96. Ouchi N, Kihara S, Arita Y, et al. Novel modulator for endothelial adhesion molecules. Adipocyte-derived plasma protein adiponectin. Circulation. 1999;100:2473–2476
  97. Malysko J, Malysko JS, Brzosko S, Wolczynski S, Mysliweic M. Adiponectin is related to CD146, a novel marker of endothelial cell activation/injury in chronic renal failure and peritoneally dialyzed patients. J Clin Endocrinol Metab. 2004;89:4620–4627
  98. Ouchi N, Kihara S, Arita Y, et al. Adipocyte-derived plasma protein, adiponectin. Suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation. 2001;103:1057–1063
  99. Arita Y, Kihara S, Ouchi N, et al. Adipocyte-derived plasma protein adiponectin acts as a platelet-derived growth factor-BB-binding protein and regulates growth factor-induced common postreceptor signal in vascular smooth muscle cell. Circulation. 2002;105:2893–2898
  100. Tsao TS, Murrey HE, Hug C, Lee DH, Lodish HF. Oligomerization state-dependent activation of the NF-kB signalling pathway by adipocyte complement-related protein of 30kDa (Arcp30). J Biol Chem. 2002;277:29359–29362
  101. Chandran M, Ciaraldi T, Phillips SA, Henry RR. Adiponectin: more than just another fat cell hormone?. Diabetes Care. 2003;26:2442–2448
  102. Maeda K, Okubo K, Shimomura I, et al. cDNA cloning and expression of a novel adipose specific collagen-like factor, apM 1 (adipose most abundant gene transcript-1). Biochem Biophys Res Commun. 1996;221:286–289
  103. Takahashi M, Arita Y, Yamagata K, et al. Genomic structure and mutations in adipose specific gene, adiponectin. Int J Obes. 2000;24:861–868
  104. Francke S, Manraj M, Lacquemant C, et al. A genome-wide scan for coronary heart disease suggests in Indo-Mauritians a susceptibility locus on chromosome 16p13 and replicates linkage with the metabolic syndrome on 3q27. Hum Mol Genet. 2001;10:2751–2765
  105. Vionnet N, Hani El-H, Dupont S, et al. Genomewide search for type 2 diabetes susceptibility genes in French whites: evidence for a novel susceptibility locus for early-onset diabetes on chromosome 3q27-qter and independent replication of a type 2 diabetes locus on chromosome 1q21q24. Am J Hum Genet. 2000;1470–1480
  106. Vassuer F, Helbecque N, Dina C, et al. Single-nucleotide polymorphism haplotypes in the both proximal promotor and exon 3 of the APM1 gene modulate adipocyte-secreted adiponectin hormone levels and contribute to the genetic risk for type 2 diabetes in French Caucasians. Hum Mol Genet. 2002;11:2607–2614
  107. Pollin TI, Tanner K, O’Connell JR, et al. Linkage of plasma adiponectin levels to 3q27 explained by association with variation in the APM1 gene. Diabetes. 2005;54:268–274
  108. Hara K, Boutin P, Mori Y, et al. Genetic variation in the gene encoding adiponectin is associated with an increased risk of type 2 diabetes in the Japanese population. Diabetes. 2002;51:536–540
  109. Berthier MT, Houde A, Cote M, et al. Impact of adiponectin gene polymorphisms on plasma lipoprotein and adiponectin concentrations of viscerally obese men. J. Lipid Res. 2005;46:237–244
  110. Yang WS, Tsou PL, Lee WJ, et al. Allele-specific differential expression of a common adiponectin gene polymorphism related to obesity. J Mol Med. 2003;81:428–434
  111. Xita N, Georgiou I, Chatzikyriakidou A, et al. Effect of adiponectin gene polymorphisms on circulating adiponectin and insulin resistance indexes in women with polycystic ovary syndrome. Clin Chem. 2005;51:416–423
  112. Stumvoll M, Tschritter O, Fritsche A, et al. Association of the T–G polymorphism in adiponectin (exon 2) with obesity and insulin sensitivity. Interaction with family history of type 2 diabetes. Diabetes. 2002;51:37–41
  113. Ukkola O, Ravussin E, Jacobson P, Sjostrom L, Bouchard C. Mutations in the adiponectin gene in lean and obese subjects from the Swedish obese subjects cohort. Metabolism. 2003;52:881–884
  114. Menzaghi C, Ercolino T, Paola RD, et al. A haplotype at the adiponectin locus is associated with obesity and other features of the insulin resistance syndrome. Diabetes. 2002;51:2306–2312
  115. Femeron F, Aubert R, Siddiq A, et al. and for the epidemiologic data on the Insulin Resistance Syndrome (DESIR) Study Group Adiponectin gene polymorphisms and adiponectin levels are independently associated with the development of hyperglycemia during a 3-year period. The epidemiologic data on the insulin resistance prospective study. Diabetes. 2004;53:1150–1157
  116. Zacharova J, Chiasson JL, Laakso M and the STOP-NIDDM Study Group. The common polymorphisms (single nucleotide polymorphism [SNP] +45 and SNP +276) of the adiponectin gene predict the conversion from impaired glucose tolerance to type 2 diabetes: the STOP-NIDDM trial. Diabetes. 2005;54:893–899
  117. Qi L, Li T, Rimm E, et al. The +276 polymorphism of the APM1 gene, plasma adiponectin concentration, and cardiovascular risk in diabetic men. Diabetes. 2005;54:1607–1610
  118. Fillippi E, Sentinelli F, Trischitta V, et al. Association of the human adiponectin gene and insulin resistance. Eur J Hum Genet. 2004;12:199–205
  119. Qiao L, Maclean PS, Schaak J, et al. C/EBPα regulates human adiponectin gene transcription through an intronic enhancer. Diabetes. 2005;54:1744–1754
  120. Vassuer F, Helbecque N, Lobbens S, et al. Hypoadiponectinaemia and high risk of type 2 diabetes are associated with adiponectin encoding (ACDC) gene promoter variants in morbid obesity: evidence for a role of ACDC in diabetisity. Diabetologia. 2005;48:892–899
  121. Gu HF, Abulaiti A, Ostenson CG, et al. Single nucleotide polymorphisms in the proximal promoter region of the adiponectin (APM1) gene are associated with type 2 diabetes in Swedish Caucasians. Diabetes. 2004;53:S31–S35
  122. Populaire C, Mori Y, Dina C, et al. Does the −11377 promotor variant of APM1 gene contribute to the genetic risk for type 2 diabetes mellitus in Japanese families?. Diabetologia. 2003;46:444–445
  123. Vozarova de C, Hanson RL, Funahashi T, et al. Common polymorphisms in the adiponectin gene ACDC are not associated with diabetes in Pima Indians. Diabetes. 2005;54:284–289
  124. Gibson F, Froguel P. Genetics of the APM1 locus and its contribution to type 2 diabetes susceptibility in French Caucasians. Diabetes. 2004;53:2977–2983
  125. Ohashi K, Ouchi N, Kihara S, et al. Adiponectin I164T mutation is associated with the metabolic syndrome and coronary artery disease. J Am Coll Cardiol. 2004;43:1195–1200
  126. Waki H, Yamauchi T, Kamon J, et al. Impaired multimerization of human adiponectin mutants associated with diabetes. J Biol Chem. 2003;278:40352–40363
  127. Fillippi E, Sentinelli F, Romeo S, et al. The adiponectin gene SNP +276G>T associates with early-onset coronary artery disease and lower levels of adiponectin in younger coronary artery disease (age≤50 years). J Mol Med. 2005;[Epub 05/05/05]
  128. Lacquemant C, Froguel P, Lobbens S, et al. The adiponectin gene SNP +45 is associated with coronary artery disease in type 2 (non-insulin dependent) diabetes mellitus. Diabet Med. 2004;21:776–781
  129. Bacci S, Menzaghi C, Ercolino T, et al. The +276G/T single nucleotide polymorphism of the adiponectin gene is associated with coronary artery disease in type 2 diabetic patients. Diabet Care. 2004;27:2015–2020
  130. Qi L, Rimm E, Liu S, Rifai N, Hu FB. Dietary glycemic index, glycemic load, cereal fiber, and plasma adiponectin concentration in diabetic men. Diabet Care. 2005;28:1022–1028
  131. Jürimäe J, Purge P, Jürimäe T. Adiponectin is altered after maximal exercise in highly trained male rowers. Eur J Appl Physiol. 2005;93:502–505
  132. Lee YY, Lee NS, Cho YM, et al. Genetic association study of adiponectin polymorphisms with risk of type 2 diabetes mellitus in Korean population. Diabet Med. 2005;22:569–575
  133. Kang ES, Park SY, Kim HJ, et al. The influence of adiponectin gene polymorphism on the rosiglitazone response in patients with type 2 diabetes. Diabet Care. 2005;28:1139–1144
  134. Mousavinasab F, Tahtinen T, Jokelainen J, et al. Common polymorphisms in the PPAR[gamma]2 and IRS-1 genes and their interaction influence serum adiponectin concentration in young Finnish men. Mol Genet Metabol. 2005;84:344–348
  135. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case–control study. The Lancet. 2004;364:937–952

PII: S0021-9150(06)00059-1

doi: 10.1016/j.atherosclerosis.2006.02.010

Atherosclerosis
Volume 188, Issue 2 , Pages 231-244 , October 2006

Article Tools

* Image Usage & Resolution